Navigation Links
Pearl Therapeutics Appoints Howie Rosen to Board of Directors
Date:11/23/2009

REDWOOD CITY, Calif., Nov. 23 /PRNewswire/ -- Pearl Therapeutics Inc., a biopharmaceutical company developing therapeutic products for the treatment of chronic respiratory diseases, today announced the appointment of Howie Rosen to the company's Board of Directors. Mr. Rosen has 25 years of experience in the pharmaceutical and biotechnology industries, including key roles at Gilead Sciences and ALZA Corporation. His appointment increases the number of directors on Pearl's Board to six.

"Howie brings a wealth of product development, commercialization and general management experience to Pearl, having held senior positions at some of the leading companies in the industry," said Perry Karsen, Chief Executive Officer of Pearl Therapeutics. "His proven track record in the drug delivery market will be invaluable to Pearl as we advance our proprietary products toward late-stage development for the treatment of chronic obstructive pulmonary disease."

"I look forward to working with Pearl's Board and management team to help develop and commercialize their very promising products for the treatment of serious, highly prevalent respiratory diseases," said Mr. Rosen. "Because of Pearl's distinctive technology platform, their products have the potential to offer patients and clinicians many compelling advantages over currently available therapies."

Mr. Rosen is currently a consultant to several companies in the industry and a lecturer in the Department of Chemical Engineering at Stanford University. He previously served as Vice President, Commercial Strategy, at Gilead Sciences, Inc., where he was responsible for strategic marketing, global brand management, health economics, competitive intelligence, market research and Gilead's overall portfolio and business planning. Prior to Gilead, Mr. Rosen spent more than 10 years in various roles at ALZA Corporation, an operating company within the Johnson & Johnson Family of Companies, most recently as President of the ALZA division of Johnson & Johnson. During his tenure at ALZA, he was responsible for product development activities, portfolio management, corporate and new product planning, mergers and acquisitions, R&D planning and technology ventures. Prior to ALZA, Mr. Rosen managed the west coast practice of Integral, Inc., served as Director of Corporate Development at GenPharm International, Inc., and was a consultant in the San Francisco office of McKinsey & Co.

Mr. Rosen also serves on the Boards of Directors of AcelRx Pharmaceuticals, Inc., PaxVax, Inc. and CNS Therapeutics, Inc.

He holds an M.B.A. from the Stanford Graduate School of Business, an M.S. in chemical engineering from the Massachusetts Institute of Technology, and a B.S. in chemical engineering from Stanford University. He is a member of the National Academy of Engineering.

About Pearl Therapeutics

Pearl Therapeutics is developing therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma. Leveraging its proprietary particle technology, formulation expertise and unparalleled product development experience, Pearl is rapidly advancing a pipeline of products that offer patients and healthcare professionals therapies that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics. Founded in 2006, Pearl Therapeutics is privately held and backed by Clarus Ventures, New Leaf Ventures and 5AM Ventures. For more information, please visit us at http://www.pearltherapeutics.com.

SOURCE Pearl Therapeutics Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pearl Therapeutics Raises $15.5 Million in Private Financing
2. String of fullerene pearls
3. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
4. MUSCs Hollings Cancer Center Dedicates Edwin and Barbara Pearlstine Healing Garden Endowed with $1 Million Gift from Edwin S. Pearlstine, Jr.
5. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
6. Pearl Therapeutics Secures $8 Million in Debt Financing
7. Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016 According ... Market Research "Separation Systems for Commercial Biotechnology Market ... and Forecast 2015 - 2023", the separation systems ... 10,665.5 Mn in 2014 and is projected to ... to 2023 to reach US$ 19,227.8 Mn in ...
(Date:4/29/2016)... Italy , April 29, 2016 ... 5.11, the latest update to its industry-leading treatment planning ... shown that Monaco version 5.11 ... can now attain calculation speeds up to four times ... . With the industry,s gold standard ...
(Date:4/28/2016)... ... April 28, 2016 , ... Next week on May 5 ... first-in-class technologies for tissue stem cell counting and expansion to gene-editing scientists and ... & CRISPR-based Genome Engineering in Burlington, Massachusetts. , The attention of most gene-editing ...
(Date:4/27/2016)... ... April 27, 2016 , ... Shimadzu Scientific Instruments (SSI) will ... Marijuana Business Conference and Expo. Shimadzu’s high-performance instruments enable laboratories to test cannabis ... attendees can stop by booth 1021 to learn how Shimadzu’s instruments can help ...
Breaking Biology Technology:
(Date:3/10/2016)... , March 10, 2016   Unisys Corporation ... and Border Protection (CBP) is testing its biometric identity ... San Diego to help identify certain non-U.S. citizens ... . The test, designed to help determine the efficiency and ... began in February and will run until May 2016. ...
(Date:3/3/2016)... MONTEREY, Calif. , March 3, 2016  FlexTech, ... in the categories of Innovation, Research & Development, Leadership ... Industry Leadership. This is the 9 th year ... select group of companies and individuals from past ... nominations based on a pre-described set of criteria, by ...
(Date:3/1/2016)... DUBLIN , March 1, 2016 ... has announced the addition of the  ... 2015-2019"  report to their offering. ... announced the addition of the  "Global ...  report to their offering. ...
Breaking Biology News(10 mins):